an increased risk of lower urinary tract symptoms (LUTS) relative to daytime workers, and are also at increased risk for shift work sleep disorder (SWSD), a primary circadian rhythm disorder indicated by excessive daytime sleepiness associated with shiftwork. Here we examine the association between SWSD and LUTS in shift workers.
INTRODUCTION AND OBJECTIVES:
Older men commonly complain of needing to urinate frequently during the night (nocturia) leading to a lack of sleep and not feeling rested in the morning. We assessed, within the context of REDUCE, a randomized controlled trial of dutasteride use, whether treating lower urinary tract symptoms (LUTS) with dutasteride altered either nocturia or sleep complaints.
METHODS: REDUCE was a randomized trial comparing dutasteride 0.5mg/day vs. placebo for chemoprevention of prostate cancer. At baseline, 2-years and 4-years, men completed the International Prostate Symptom Score (IPSS) survey and the MOSSS-6 questionnaire, a 6-item scale that assesses sleep and is scored 1-100. To test the differences in IPSS (and specifically nocturia) and MOSSS over the study, we used linear mixed models with predictors of treatment, visit, and the interaction between treatment and visit. Models were adjusted for baseline age, digital rectal exam findings, PSA, body mass index, race, smoking status, prostate volume, diabetes, and geographical region. Linear contrasts were used to summarize the effect of treatment on each outcome at each study visit. Subanalyses were conducted in men who were symptomatic (IPSS !8) and men with !2 nocturia episodes a night at baseline.
RESULTS: There were 6915 patients with complete baseline data. Baseline characteristics were balanced between treatment arms. Dutasteride resulted in significant improvements in IPSS at 2-years (p<0.001) and 4-years (p<0.001) as well as specifically nocturia episodes at 2-years and (p¼0.005) 4-years (p<0.001). In contrast, treatment with dutasteride had no effect on overall sleep function nor any specific domain of sleep including feeling rested in the morning or getting enough sleep (p>0.1 at all visits). When analyses were limited to symptomatic men (IPSS !8) or men with !2 nocturia episodes per night, results were unchanged in that dutasteride improved LUTS including nocturia but had no effect on sleep function including feeling rested in the morning or getting enough sleep.
CONCLUSIONS: In men who complain of nocturia resulting in not getting enough sleep, treatment of LUTS with dutasteride significantly improves LUTS but has no effect on sleep including feeling rested in the morning or getting enough sleep. These results suggest in men with nocturia who complain of poor sleep, the poor sleep is not likely to be due to LUTS but rather likely represents a primary sleep problem. Consideration should be given to referring these men to sleep experts to evaluate for sleep problems like sleep apnea or insomnia.
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MP13-14 STUDYING THE EFFECT OF DIABETES MELLITUS TYPE 2 ON PROSTATE RELATED PARAMETERS: A PROSPECTIVE SINGLE INSTITUTIONAL STUDY.
INTRODUCTION AND OBJECTIVES: Diabetes mellitus (DM)
is a serious culprit of male health. A positive association exists between clinical markers of BPH and DM. The aim of this work is to examine the effects of type 2 diabetes mellitus (DM) on the variables associated with prostatic growth including serum PSA, serum testosterone and prostate volume and to correlate these variables with the duration of diabetic treatment.
METHODS: Our study was conducted over 3 months recruiting 501 men aged 55 years old or more, of which 207 patients had type 2 DM. Exclusion criteria were active urinary tract infection, suspicious rectal examination, urologic cancers, end organ damage and recent urologic manipulations. Serum PSA and serum testosterone were measured. Prostate volume was determined by abdominal ultrasonography using ellipsoid formula. This study was approved by the ethical committee and informed consents were obtained from participating patients.
RESULTS: The mean patient age was 60.21 AE 5.95 years. The mean PSA, Testosterone and prostate volume for diabetic men were 2.3 ng/ ml, 3 ng/ ml and 56 grams respectively. These were 3.5 ng/ ml, 4 ng/ ml and 51 grams respectively for non-diabetics. (p 0.001, p 0.001, p 0.03 respectively). The mean PSA density was 0.049 AE 0.043 ng/ml/ cm3 in diabetics versus 0.080 AE 0.056 ng/ml/cm3 in non-diabetics (p<0.001). As high BMI in diabetic patients was a confounding factor, multiple regression analysis was done (table 1) , confirming the true significant correlation of DM with the studied parameters.
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